Agoracom Blog Home

Posts Tagged ‘investments’

Empower Clinics $CBDT.ca $EPWCF Signs Definitive Agreement to Acquire Momentum Health With 7 Canadian Clinics. Begins Planning for Nationwide Rollout $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 4:16 PM on Thursday, December 17th, 2020

Acquisition Will Expand Company’s North American Footprint And Strengthen Vertical Integration From Patients To Laboratory, Strengthening Testing and Bubble Initiatives

  • Announced the execution of a definitive share purchase agreement dated December 16, 2020 to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc.
  • Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being.
  • Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others.
  • Acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

VANCOUVER, BC / December 17, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA and Health Canada approval, is pleased to announce the execution of a definitive share purchase agreement dated December 16, 2020 (the “Agreement“) to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. (collectively “Momentum Health“).

Steven McAuley, Chairman and CEO of Empower stated “The acquisition of Momentum Health will be a significant milestone for both Empower and its shareholders that we expect will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession. It is anticipated that this immediate and rapid nationwide expansion plan will be made possible by combining the winning Momentum Health model with the financial, marketing and operational control resources already successfully deployed by Empower in building its US operations, including the successful win of a $1.2 million testing contract with a film and television studio within just 45 days of acquiring our KAI Medical Lab. Significant discussions are already underway with potential nationwide partners and we expect to have developments in the very near future.”

ACQUISITION INCLUDES 7 CLINICS IN GREATER TORONTO AREA WITH IMMEDIATE PLANS TO EXPAND “CLINIC-IN-CLINIC” MODEL ACROSS CANADA.

Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being. Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others. The full range of services can be viewed at www.momentumhealthclinic.com.

The acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

More importantly, it is expected that expansion will be at a very attractive and cost-effective model of opening “clinics-within-clinics” in which the Company proposes to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility. This model results in a win-win for both Empower and the primary care facility partner as follows:

  • Substantially improved care for patients of the primary care facility
  • Significantly reduced start-up costs for Empower
  • Immediate access to the large patient base of the primary care facility
  • Immediate rental income for the primary care facility

With this proven winning model, the nationwide roll-out it is planned to commence immediately upon closing of the acquisition with expansion in the Greater Toronto Area, followed by expansion throughout Ontario and finally West through all Provinces with a standardized brand and technology platform.

Moreover, the acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

CEO McAuley added “Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empower’s clinic footprint across Canada will be invaluable toward meeting our ambitious objectives.”

Momentum Co-Founder Dr. Robinowitz commented “Joining Empower provides us with the opportunity to scale an intricately designed health care model alongside the outstanding professionals currently on their team. This transaction will not only allow our current patients to have increased access to integrative care, we also strive to exponentially increase our patient base with strategic, nationwide expansion.”

Momentum Co-Founder Dr. Tsimerman commented “I am thrilled to be joining Empower Clinics with a shared vision of nationwide, truly integrative medical care based on patient – centric services. This unique opportunity allows us to provide an unparalleled patient experience and create a leading approach to modernized health care.”

TERMS OF ACQUISITION

Pursuant to the terms of the Agreement, Empower will pay the vendors of Momentum Health $275,000 cash at closing (including $44,648 to settle an outstanding debt of Momentum Health) with an additional $75,000 to be withheld as a holdback for adjustments, for an aggregate cash payment of $350,000. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman or their affiliates 5,128,204 common shares in the capital of Empower (at a deemed price of $0.0975 per share), 2,564,102 of which will be subject to contractual resale restrictions resulting in them being released quarterly from the date of closing in eight (8) equal instalments.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The acquisition also includes long-term performance incentives for Dr. Rabinowitz and Dr. Tsimerman. If, within 18 months from the closing date, the Company or its affiliates have opened and have operating an aggregate of ten (10) new clinic locations in Canada (“Milestone One”), each of Dr. Rabinowitz and Dr. Tsimerman shall be entitled to receive incentive stock options of Empower to purchase 1,875,000 common shares of Empower, vesting as follows:

  1. 1/3 immediately;
  2. 1/3 upon of the Company or its affiliates having opened and operating an aggregate of twenty (20) new clinic locations in Canada; and
  3. 1/3 upon of the Company or its affiliates having opened and operating an aggregate of thirty (30) new clinic locations in Canada.

ADDITIONAL DETAILS

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman on closing of the acquisition, to lead the Canadian clinic expansion strategy.

Completion of the acquisition contemplated by the Agreement is subject to customary closing conditions which the Company anticipates being completed on or before December 21, 2020.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company’s nationwide rollout and timing and results of such rollout; the Company expecting the acquisition will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession; the Company’s expectation for the costs of expansion; and the Company’s plans to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility and the results of such model. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

AGORACOM Small Cap 60: Datametrex $DM.ca $DTMXF Discusses Record Q3 Revenue of $4.9M $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 1:13 PM on Thursday, December 17th, 2020

Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC ) an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution.  When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter 

Hub On AGORACOM / Corporate Profile

Quebec Pharmacists Launch #ECG Screening for the Prevention of Drug Induced Sudden Cardiac Death – CardioComm Solutions $EKG.ca $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:04 AM on Thursday, December 17th, 2020

HeartCheck™ CardiBeat and SMART Monitoring ECG Triaging to be used in Screening Services for detection of QT Prolongation in Community Pharmacies

  • Confirms the start of a pharmacy-based ECG monitoring service to screen for prolonged QT interval for the prevention of drug induced sudden cardiac death.
  • Under the Company’s Allied Health Professional Partner Program, the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app will be used to collect ECGs recorded by patients under the direction of a pharmacist.
  • Recorded ECGs will be passed from the GEMS™ Mobile app to the Company’s SMART Monitoring ECG reading service to be triaged.
  • All findings will be sent directly to the pharmacist and any submitted ECG recordings that show a presence of prolonged QT interval or any other cardiac arrhythmia will be flagged so that the pharmacist may then follow up as needed with the patient’s treating physician.

TORONTO, ON / December 17, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) (“CardioComm” or the “Company“), a global provider of consumer heart monitoring and electrocardiogram (“ECG“) device and software solutions, confirms the start of a pharmacy-based ECG monitoring service to screen for prolonged QT interval for the prevention of drug induced sudden cardiac death.

Under the Company’s Allied Health Professional Partner Program, the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app will be used to collect ECGs recorded by patients under the direction of a pharmacist. Recorded ECGs will be passed from the GEMS™ Mobile app to the Company’s SMART Monitoring ECG reading service to be triaged. All findings will be sent directly to the pharmacist and any submitted ECG recordings that show a presence of prolonged QT interval or any other cardiac arrhythmia will be flagged so that the pharmacist may then follow up as needed with the patient’s treating physician.

Pharmacists plan to run ECG tests on patients when picking up a prescription. All QT and QTc interval findings will be kept on file with the goal of recording QT measurements for any patient with known cardiac issues and starting any new medication known to influence the QT interval. “As polypharmacy analysis becomes more prevalent in a pharmacist’s daily tasks, the use of the HeartCheck™ CardiBeat device will allow staff to quickly measure the patient’s QT/QTc and make a clinical judgment as per the safety of the prescriptions being dispensed”, states pharmacist K. Manoukian.

QT interval prolongation is a recognized adverse drug reaction and risk factor for torsades de pointes (TdP), a fatal arrhythmia that can result in sudden cardiac death. While rare, the severity of TdP makes QT prolongation a serious concern when prescribing medications.

Pharmacists have a legal and professional responsibility to evaluate/mitigate medication adverse and serious adverse event risk factors and are the final decision makers in dispensing or not dispensing medications. The surface ECG is the only way to confirm or rule out the presence of a prolonged QT interval. The HeartCheck™ CardiBeat provides a useful tool as QT prolongation can now be easily, quickly and cost effectively obtained in community pharmacies and be compared to well established normal duration ranges. Without an ECG sudden cardiac death due to a prolonged QT interval may be the first and only evidence of the disease. Prior to the release of CardioComm’s ECG screening technologies, QT interval prolongation ECG screening was not available outside of the hospital setting.

Listings of medications known to cause TdP through acquired QT syndrome prolongation in healthy people (crediblemeds.org, sads.org.uk and heartcentre.ca) contain more than 100 common medications, many of which are dispensed by pharmacists. These include common antibiotics, medications to treat yeast infections, diuretics, anti-arrhythmia heart medications, and antidepressant and antipsychotic medications. Additionally, COVID-19 infection, a history of cardiac arrest and cardiovascular disease, age and women on heart medications are also known to increase the risk for cause acquired QT interval prolongation.

Through the screening service CardioComm will earn revenue from a per ECG QT interval triaging service fee. With the program now launched in Quebec, the Company will next look to the introduction of the QT interval ECG screening services in pharmacies and physician practices in other provinces.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: CardioComm Solutions, Inc.

Datametrex AI $DM.ca $DTMXF Ramps up COVID-19 Testing for Film & Television Sectors $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:22 AM on Thursday, December 17th, 2020
  • As of this coming January 2021, the Company has received order for an additional 3 film & TV productions in Toronto and an additional 6 l film & TV productions in Vancouver.
  • The Company is currently providing services to 6 production companies in Toronto and 11 production companies in Vancouver, administering approximately 6,000 tests per week.
  • The Company expects this will increase significantly with the additional projects which is seeing in its project pipeline.

Toronto, Ontario–(December 17, 2020) – Datametrex AI Limited  (TSXV: DM) (FSE: D4G) (OTC: DTMXF) (the “Company” or “Datametrex”) wishes to provide an update on film and television industry testing and lab facilities projects which it is undertaking in Canada.

As of this coming January 2021, the Company has received order for an additional 3 film & TV productions in Toronto and an additional 6 l film & TV productions in Vancouver. The Company is currently providing services to 6 production companies in Toronto and 11 production companies in Vancouver, administering approximately 6,000 tests per week. The Company expects this will increase significantly with the additional projects which is seeing in its project pipeline.

Datametrex has ramped up testing lab facilities in Vancouver. The lab now has a capacity of processing up to 10,000 COVID-19 tests per week with the ability to expand this capacity even further (if required).

Vancouver is the third-largest production centre in North America, worth CDN $3.2 billion during 2018/19, according to Creative BC. British Columbia is home to several world-class Film and TV studios, including Bridge Studios, Mammoth Studios, Vancouver Film Studios, North Shore Studios, Ironwood Studios, Canadian Motion Picture Park, and The Crossing Studios. (Source: CreativeBC Film Commission)

Entire film and TV production in Canada represent $8.92 billion in production volume, and full-time equivalent jobs represent 179,000 workers. In March 2020, the industry stopped worldwide and in Vancouver which represents 37% of Canadian productions, and the surrounding areas had 46 productions filming which does not include the TV commercial market. Each of the shows would have a minimum of a 100-person film crew. (Source: CreativeBC Film Commission)

The next largest film and television market is Ontario which represents 34% of Canadian productions and in 2019, Toronto’s film and television industry directly employed more than 28,000 people representing $3.17 billion in production volume. (Source: CreativeBC Film Commission)

“With Vancouver and Toronto feature-length movies and episodic series productions filming quickly ramping up, we feel that this will only expand the COVID-19 screening business for the film and TV industries,” said Marshall Gunter CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.

Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.

Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Datametrex AI $DM.ca $DTMXF Announces Release of Nexalogy “SMART” Technology $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:28 AM on Wednesday, December 16th, 2020
  • Announced the release of Nexalogy SMART – Social Media Automated Reporting Technology
  • As previously announced, Nexalogy’s SMART is an advanced proprietary AI technology
  • SMART minimizes human involvement in data analysis and reporting.
  • It significantly decreases the time required for integration and interpretation of large data sets and report production
  • Now fully available

Toronto, Ontario–(December 16, 2020) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce the release of Nexalogy SMART – Social Media Automated Reporting Technology.

As previously announced, Nexalogy’s SMART is an advanced proprietary AI technology. SMART minimizes human involvement in data analysis and reporting. It significantly decreases the time required for integration and interpretation of large data sets and report production. It is now fully available.

SMART takes NexaIntelligence to the next level with AI-powered automated reporting technology. It quickly generates reports with all of NexaIntelligence’s visualizations, augmenting the reporting capacity of analysts. Human resources are a scarce commodity. SMART integrates larger sets of data into smaller, more manageable reports, thus significantly reducing the number of resource hours required to identify insights.

Our AI pre-reads text, selects verbatims, and summarizes themes quickly, reliably, and with precision. The AI technology creates powerful reports based on our algorithms and automatically selects the most important original posts to include, in minutes rather than hours. Analysts can specify filters on the data to get automatic reports on subsets of the data focusing on specific times, entities, social media users, or topics. This means social media trends can be understood faster and with less difficulty, keeping companies ahead of the curve.

SMART’s scheduling functionality allows companies to structure reporting to match regular schedules as needed or in response to triggering events in the data itself. AI-written reports are emailed to analysts inconvenient and easy to read file formats, such as MSWORD or PDF. Raw JSON outputs from Nexalogy’s API are also available for use in white labelled products.

AI reporting on social media and other forms of unstructured text is increasingly important and relevant in the information landscape. The need for strategic reporting of data from these platforms in both the public and private sectors is growing at a rapid pace. The ability to analyze and monetize social media discussions, as well as unstructured text from owned sources, are key strengths of SMART. Breaking through information bottlenecks and resource limitations, SMART can take big data discovery and exploration to a new level of actionable insights.

“Our AI helps you unlock the power of discovery, converting unknown unknowns into known knowns, activating the hidden potential currently lost in big data. With social media and unstructured text being a key facet of how businesses and consumers connect during the pandemic, we feel SMART is uniquely positioned to assist clients in unlocking potential in current verticals and exploring the potential of new verticals; for security, we help you discover unknown problems so you can squash them before they become big problems. For growth, we help you discover and unlock hidden potential,” said Marshall Gunter, CEO of Datametrex AI Limited.

To see more and download example reports, click here: https://nexalogy.com/product/

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

###

CardioComm Solutions $EKG.ca to Bring #ECG Monitoring to Remote Patient and #COVID-19 Monitoring Platforms $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 8:38 PM on Tuesday, December 15th, 2020
  • Entered into a technology integration agreement with LiveCare Corp. and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med, to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform.
  • CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed.
  • Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service.
  • Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform’s remote patient monitoring teams.

TORONTO, ON / December 15, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) (“CardioComm” or the “Company“), a global provider of consumer heart monitoring and electrocardiogram (“ECG“) device and software solutions, is pleased to confirm it has entered into a technology integration agreement with LiveCare Corp. (“LiveCare“) and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med (“Alliance“), to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform.

CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed. Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service. Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform’s remote patient monitoring teams.

Link+ is a patented smart home gateway that integrates multiple key medical bio-sign monitoring devices in a patient’s home through a proprietary, touch-free device which is always connected to the 4G network. There is no need for patients to connect to any specific Wi-Fi network for the Link+ to fully operate and, once activated, the Link+ transmits data directly to LiveCare’s HIPAA compliant cloud. The Link+ is fully reimbursable through Medicare, Medicaid and many commercial insurance plans using multiple CPT codes.

Through the addition of the GEMS™ technology into the Link+ gateway device, the Link+ device will be capable of recognizing multiple ECG devices with up to 12 leads of ECG recording and provide Link+ customers with more options in choosing a device of their preference. The HeartCheck™ CardiBeat will be the recommended device for remote ECG patient monitoring given its availability in Canada, the US and Europe. All recorded ECGs will be passed through CardioComm’s SMART Monitoring ECG triaging service. ECG reports confirming the presence or absence of an arrhythmia will be provided to Link+ users.

The Link+ platform with ECG monitoring sales and marketing will be undertaken exclusively by Alliance with a focus on monitoring patients with or suspected to have COVID-19. Sales into the US is where the primary marketing efforts are targeted for 2021. CardioComm will see revenue from the sales of the HeartCheck™ CardiBeat ECG devices as well as from ECG triaging service fees.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

About LiveCare (www.livecareusa.com)

LiveCare’s mission is to improve patient outcomes, lower healthcare costs, and reduce hospital readmissions by developing technology to assist patients and providers during the critical transitional care period. LiveCare’s technology improves patient compliance with post-discharge medical protocols and enhances engagement between patients and providers. With a team of experienced professionals working in research and development, sales, and other capacities, LiveCare is putting the needs of patients and providers at the forefront as it moves the RPM market forward from its corporate headquarters in New York City.

About Alliance-Telemed, LLC

Alliance Tele-Med is a US-based Value-Added Wholesaler & Reseller of state-of-the-art remote patient monitoring (RPM) technology and care management services solutions for domestic and international healthcare delivery organizations and their patients. The company engages with healthcare and life sciences organizations such as Independent and Hospital-Owned Medical Practices, Independent Hospitals and Health Systems, Accountable Care Organizations (ACO’S), Independent Physician Associations (IPA’s), Provider Networks, large Employer Groups and Third Party Administrators, Clinics, FQHC and Regional Health Centers, Senior ‘Aging in Place’ Companies and Facilities such as Assisted Living Facilities, Nursing Homes, Skilled Nursing Facilities, Home Health Companies, pharmaceutical companies, and Clinical Research Organizations (CRO’s).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Datametrex $DM.ca $DTMXF Awarded Two Contracts with Insurance Provider and Airport Authority $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:51 AM on Tuesday, December 15th, 2020
  • Announced that it has been awarded two AI related contracts totalling $150,000 on the initial pilot contracts.
  • The first contract is for tech support for Incheon International Airport Corporation, a major airport in the Republic of Korea.
  • Company was also awarded a contract with ABL Life Insurance Co., Ltd. for job automation scheduling.
  • The Company commenced the work, and is already in negotiation to expand the scope of work and contract.

Toronto, Ontario–(December 15, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has been awarded two AI related contracts totalling $150,000 on the initial pilot contracts.

The first contract is for tech support for Incheon International Airport Corporation (“IIAC”), a major airport in the Republic of Korea.

Under the terms of the contract, Datametrex will provide AI for job automation scheduling using AI technologies in partnership with third party software from Sees solutions for Workload Automation-As-A-Service (“WAAAS”). The batch job scheduler will help automate the workflow with all batch jobs that are software managed and approve the results of the execution by WAAAS. Integrated batch job scheduler systems are linked to the existing legacy system and each target system is configured to execute batch jobs. Once operational, the system will feature integrated batch job management, flexible approval system, efficient calendar management, secure security, optimal performance, and agent add-in are features that manage file transfer functions.

The Company was also awarded a contract with ABL Life Insurance Co., Ltd. (“ABL”) for job automation scheduling. The Company commenced the work, and is already in negotiation to expand the scope of work and contract.

About Incheon International Airport Corporation

Seoul Airport, known officially as Incheon International Airport (IATA: ICN, ICAO: RKSI), and is the largest and the primary airport serving Seoul, the capital of South Korea. The airport employs over 40,000 people and include airport management staff, security personnel and system managers.

It is located west of Incheon city and 30 miles (48 km) west of Seoul. Incheon Airport consists of two passenger terminals, and has 111 boarding gates altogether, with 44 in Terminal 1, 30 in Concourse A (connected to Terminal 1), and 37 in Terminal 2. It has been rated as the one of the world’s cleanest airports and highly rated international transit airports by Skytrax. In 2019, the airport served a total of 70,857,908 passengers and ranked 8th in international passengers and 3rd in international cargo. Additional information on Incheon is available at www.airport.kr/

About ABL Life Insurance Co., Ltd

Founded in 1954, ABL Life provides insurance products and financial services to 1.13 million customers based on a nationwide sales network. ABL Life Insurance is striving to become “a reliable global life insurance company that provides ‘better life’ through advanced products and smart services.” Additional information on ABL is available at www.abllife.co.kr/

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.

Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.

Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

###

Empower Clinics $CBDT.ca $EPWCF Announces Receipt of Over $5,500,000 From Exercise of Warrants, Launches New Corporate Website for Future Integrated Healthcare $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:32 AM on Monday, December 14th, 2020
  • Announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020
  • The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company
  • It serves as an indication of the strength of Empower’s shareholder base and its following
  • Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond

VANCOUVER BC / December 14, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and validating novel COVID-19 testing protocols for CE, FDA and Health Canada approval is pleased to announce the following:

RECEIPT OF $5,500,000 + FROM THE EXERCISE OF WARRANTS ALLOWS EMPOWER TO CONTINUE TO EXECUTE WITH INCREASED STRENGTH

Empower is pleased to announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020. The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company. It serves as an indication of the strength of Empower’s shareholder base and its following.

The Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it has the war chest necessary to pursue numerous opportunities. KAI medical laboratory continues to expand nationwide in the U.S., Empower is growing physician services and direct access to patients through new clinics expansions and the company will provide dynamic technology-based healthcare services to meet patient needs.

Steven McAuley, Chairman and CEO of Empower stated, “The timing of these warrant exercises could not be better as we head into our biggest growth phase ever, thanks to rapidly growing demand for our KAI Medical Lab COVID-19 testing solutions, as well as, the impending launch of our FDA approved KAI Saliva Test plus the pending clinic group acquisition in Canada. These proceeds significantly bolster our financial strength, resources and confidence necessary to aggressively pursue our growth strategies in 2021.”

EMPOWER LAUNCHES NEW WEBSITE TO BETTER REFLECT COMPANY’S 2021 DIRECTION

The Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond, as well as, our defined vision as follows:

GROWTH PILLARS

Health & Wellness Is Our Purpose – Through our clinics in the US and telemedicine platform, our physicians treat patients in Oregon, Arizona and Washington State. Within this section you can read our statements about integrated care and patient first care.

Diagnostics & Tech Is Our Vision – The October 5th acquisition of Texas-based KAI Medical Laboratory was a significant achievement for Empower, as it firmly and immediately established the science and research side of Empower. In its first month, KAI delivered record revenues and soon after announced its first $1,000,000 COVID-19 testing contract for a major film and television studio.

This section is rich in information for investors that want to better familiarize themselves with the capabilities of KAI Laboratory and COVID-19 testing capabilities that attracted major contracts and R&D initiatives.

We invite all of our shareholders and prospective investors to visit our new website at https://www.empowerclinics.com/

EMPOWER TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM

The Company is commencing discussions on its “CEO Verified Forum” on AGORACOM, which is intended to serve as one of the Company’s social media platforms for interaction with current and prospective shareholders.

Steven McAuley added “The growth experienced by Empower over the past 12 months has come from all sources providing the best possible engagement with our clients, followers, investors and all social platforms. I enjoy responding to shareholder inquiries, and the demand for engagement and discussion by investors has grown significantly. Engaging with Agoracom followers is an invaluable tool given our anticipated developments and I look forward to posting my comments and interactions with shareholders.”

The Empower Clinics Verified Forum can be found at https://agoracom.com/ir/EmpowerClinics/forums/discussion

About Empower

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients and provide long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Dustin Klein
Director
[email protected]
720-352-1398

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Datametrex $DM.ca $DTMXF Provides Clarity on a Statement Published on Twitter by Air Canada $AC.ca $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:47 AM on Friday, December 11th, 2020
  • Though the Company has not commented on the tweet publicly, several inquires on the tweet have been put to management.
  • What the Company can confirm is that Datametrex is completing an agreement to support Canadian communities and provide pre-departure coronavirus (COVID-19) PCR-based testing for travellers in several large metropolitan centers within Canada.
  • These tests will be available for travellers flying to any destination requiring a negative COVID-19 test.

Toronto, Ontario–(December 11, 2020) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) wishes to provide clarity on a statement that was published on Twitter by Air Canada regarding COVID-19 testing and Datametrex on November 22, 2020.

The official Air Canada Twitter channel @AirCanada replied to a tweet on a question posted regarding COVID-19 trusted testing partners for travel to the state of Hawaii. Air Canada provided the following reply, “The state of Hawaii will only accept COVID-19 PCR – Nucleic Acid Amplification Test (NAAT) from a certified Clinical Laboratory from trusted testing and travel partners. In Canada those are: LIFE LABS, DYNACARE, Datametrex Al limited, Biron, and DynaLIFE MEDICAL LABS. /Ariana.”



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/1778/70044_9b819cd56413e8c8_002full.jpg

Though the Company has not commented on the tweet publicly, several inquires on the tweet have been put to management. What the Company can confirm is that Datametrex is completing an agreement to support Canadian communities and provide pre-departure coronavirus (COVID-19) PCR-based testing for travellers in several large metropolitan centers within Canada. These tests will be available for travellers flying to any destination requiring a negative COVID-19 test.

As a trusted testing and travel partner, Datametrex will provide further commentary in a news release on locations and specifics to the COVID-19 testing for travellers. Datametrex believes that testing and peace of mind are important to your health and wellness.

Important COVID-19 Considerations

Note: Health Canada does not advise you to get a COVID-19 test if you do not have symptoms of the virus. Since a negative result is required for the Hawaiian pre-testing program, this would go against public health advice.

The Government of Canada also warns against travel outside of the country. Due to the COVID-19 pandemic, governments that have opened their borders to tourists could impose strict travel restrictions suddenly, which could make it difficult for you to return home.

Under measures from provincial Governments in Canada, all arriving passengers from outside of Canada, regardless of their final destination, are required to submit a self-isolation plan. It must show that returning passengers have supports in place to safely self-isolate for 14 days.

About Air Canada

Air Canada is Canada’s largest domestic and international airline. Canada’s flag carrier is among the 20 largest airlines in the world and in 2019 served over 51 million customers. Air Canada is a founding member of Star Alliance, the world’s most comprehensive air transportation network. Air Canada is the only international network carrier in North America to receive a Four-Star ranking according to independent U.K. research firm Skytrax, which also named Air Canada the 2019 Best Airline in North America. For more information, please visit: aircanada.com/media.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.

Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.

Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

###

.

VIDEO – Datametrex $DM.ca $DTMXF Discusses Record Q3 and YTD Results, Looks Forward To 2021 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:26 PM on Thursday, December 10th, 2020
Webinar logo

Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter

Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.